Larvol Delta - Celldex-Presents-LongTerm-Barzolvolimab-Results-Demonstrating-Sustained-OffTreatment-Improvement-in-Angioedema-in-Patients-with-CSU-at-the-European-Academy-of-Allergy-and-Clinical-Immunology-Annual-Meeting

barzolvolimab (CDX-0159) - Celldex

https://www.globenewswire.com/news-release/2026/06/14/3311449/24180/en/celldex-presents-long-term-barzolvolimab-results-demonstrating-sustained-off-treatment-improvement-in-angioedema-in-patients-with-csu-at-the-european-academy-of-allergy-and-clinica.html

Jun 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next